Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Immunhälsa biomarkörer och fekal mikrobiota hos filippinska ammade spädbarn

16 september 2026 uppdaterad av: Société des Produits Nestlé (SPN)

Immunhälsa biomarkörer och fekal mikrobiota hos filippinska ammade spädbarn: en prospektiv observationsstudie

This will be a prospective observational study aiming to investigate immune health biomarkers and fecal microbiota in 48-60 Filipino breastfed infants from birth to 12 months of age. An optional follow-up period of approximately 2 years will follow.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This will be a prospective observational study in healthy term infants who are exclusively breastfed. Approximately 48-60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment will be recruited and followed up until 12 month of age at 6 on-site visits: V1 (baseline), V3 (2 months), V5 (4 months), V6 (6 month), V7 (10months) and V8 (12 months).

The 12-month observational period will be followed by a 2year optional follow-up period for a total duration of the study of approximately 3 years.

The primary objective of this clinical study is to characterize early immune system development in breastfed Filipino infants by investigating infant blood markers of systemic immunity.

The secondary objectives will include the characterization of infant fecal markers of immune health and gut barrier function, infant blood and fecal microbiome, interactions between immune development and microbiome maturation, infant fecal metabolic profile and fecal pH, infant gastrointestinal (GI) tolerance, infant anthropometric measurements, infant complementary food intake as well as infant illness and infection.

Studietyp

Observationell

Inskrivning (Faktisk)

60

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Filippinerna
    • Manila
      • Manila, Manila, Filippinerna, 1780
        • Asian Hospital and Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

2 veckor till 1 månad (Barn)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Approximately 60 healthy breastfed infants aged ≥14 to ≤35 days at enrollment. To ensure balanced sex representation of the study population, approximately 30 males and 30 females will be enrolled in the study.

Beskrivning

Inclusion Criteria:

  1. Written informed consent is obtained from parent(s)/ legally authorized representative(s) (LAR(s)).

  2. Parent(s)/ LAR(s) must be able to provide evidence of parental authority and identity.

  3. Parents/ LARs must understand the informed consent and other study documents.

  4. Infants whose parent(s)/ LAR (s) has consented to blood collection as per protocol.

  5. Able to temporarily store stool samples in a household freezer.

  6. Infants whose parent(s)/LAR(s) are willing and able to comply with scheduled visits, and the requirements of the study protocol.

  7. Infants whose parent(s)/LAR(s) can be contacted directly by telephone throughout the study.

  8. Infants must meet all the following inclusion criteria to be eligible for enrollment into the study:

    1. Healthy term infant (≥37 weeks of gestation)
    2. At enrollment visit, postnatal age ≥14 to ≤35 days (date of birth = day 0)
    3. Birth weight is appropriate for gestational age (i.e., ≥ 2500g and ≤ 4500g)
    4. Infant has exclusively received breastmilk from birth to enrollment, and parent intends to continue exclusive breastmilk feeding until infant age 6 months.

Exclusion Criteria:

  1. A medical condition or history that could increase the risk associated with study participation or interfere with the interpretation of study results, including:

    1. Evidence of major congenital malformations (e.g., cleft palate, extremity malformation).
    2. Suspected or documented systemic or congenital infections (e.g., human immunodeficiency virus, cytomegalovirus, syphilis).
    3. Previous or ongoing severe medical or laboratory abnormality (acute or chronic) which, in the judgment of the investigator, would make the infant inappropriate for entry into the study. Of note, children who are normally healthy but at the time of enrolment suffering from acute illness in a minor condition which are common in childhood and do not require some of the exclusionary medication mentioned below can be enrolled.

  2. Presently receiving or have received prior to enrolment any of the following: medication(s) or supplement(s) which are known or suspected to affect the following: fat digestion, absorption, and/or metabolism (e.g., pancreatic enzymes); stool microbiota and characteristics (e.g., oral, or systemic antibiotics, glycerin suppositories, bismuth-containing medications, docusate, Maltsupex, or lactulose); growth (e.g., insulin or growth hormone); gastric acid secretion.

  3. Infants whose parent(s) has(ve) not reached legal age of majority (18 years old) upon enrollment.

  4. Currently participating or having participated in any interventional clinical trials since birth.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiv: PROSPECTIVE

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Markers of systemic immunity
Tidsram: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months

Descriptive statistics of plasma immune proteomics using mass cytometry or immunoassays, and vaccine-specific antibodies assessed by ELISA
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months and 12months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fecal markers of immune health and gut barrier
Tidsram: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
  • Fecal markers of immune health and gut barrier, such as but not restricted to calprotectin and α-1-antitrypsin assessed by ELISA or alternative methods
  • Fecal cytokine profile using multiplex assays
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
Infant fecal microbiome
Tidsram: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months

Microbiota composition, diversity, community types, and abundance of bacteria taxa
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12months
Fecal metabolic profile and pH
Tidsram: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months

pH and fecal organic acids, such as lactate, propionate, butyrate, acetate, valerate and total fecal organic acids, in wet stool weight and per dry stool weight
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, 10 months and 12 months
Plasma Metabolomics
Tidsram: Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months

Untargeted Plasma metabolomics Analyses
Infant age ≥14 to ≤35 days, 2 months, 4 months, 6 months, and 12 months
GI Tolerance
Tidsram: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
  • Stool frequency and consistency, GI symptoms and GI-related behaviors collected via 1-day and 3-day GI Symptom and Behavior Diaries
  • GI burden score derived from the Infant Gastrointestinal Symptom Questionnaire (IGSQ-13)
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
Weight
Tidsram: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months

Measurement of weight in grams
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
Length
Tidsram: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months

Measurement of length in cm
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
Head circumference
Tidsram: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months

Measurement of head circumference in cm
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months
Z-scores and percentiles
Tidsram: Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.

Changes in weight-for-age, weight-for-length, length-for-age, BMI-for-age, and head-circumference-for-age z-scores and percentiles calculated according to WHO standards
Infant age ≥14 to ≤35 days, 1.5 months, 2 months, 3 months, 4 months, 6 months, 10 months and 12 months.
Infant illness and infection
Tidsram: Infant age 6 months

Descriptive data and overall score derived from the Pediatric Immune System Index Questionnaire completed by parents
Infant age 6 months
Infant Complementary Food Intake
Tidsram: Infant age 6-12months

Descriptive data from complementary food questionnaire and 3-day food record
Infant age 6-12months
Long-term infant illness (during the optional follow-up)
Tidsram: Infant age 12 months, 18 months, 24 months, 30 months, and 36 months

Descriptive data from the Infant Illness Questionnaire completed by parents
Infant age 12 months, 18 months, 24 months, 30 months, and 36 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of Adverse Events
Tidsram: From infant age ≥14 to ≤35 days to 12 months

Incidents of adverse events from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months
From infant age ≥14 to ≤35 days to 12 months
Concomitant medications and treatments
Tidsram: From infant age ≥14 to ≤35 days to 12 months

All concomitant medications / treatments (including type and duration) used to treat illnesses and other conditions will be recorded continuously from time of ICF signing at baseline, age ≥14 to ≤35 days, through the last study visit at age 12 months
From infant age ≥14 to ≤35 days to 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Société des Produits Nestlé (SPN)

Samarbetspartners

Asian Hospital and Medical Center, Muntinlupa City, Philippines

Utredare

  • Huvudutredare: Maria Rosario JK Capeding, MD, Asian Hospital and Medical Center, Philippines

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 november 2024

Primärt slutförande (Faktisk)

30 januari 2026

Avslutad studie (Beräknad)

31 december 2027

Studieregistreringsdatum

Först inskickad

5 november 2024

Först inskickad som uppfyllde QC-kriterierna

25 november 2024

Första postat (Faktisk)

27 november 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

21 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 2313INF

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera